ArticlePediatric transplantation2026
Integrating Tissue Gene Expression Profiling With Histopathology in Pediatric Kidney Recipients.
Article in Pediatric transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBanff classification is the standard for diagnosing kidney allograft rejection, but histologic evaluation is limited by sampling error, interobserver variability, and interpretive subjectivity. The Molecular Microscope Diagnostic System (MMDx) evaluates tissue gene expression to classify rejection phenotypes and may clarify ambiguous histologic findings. Although utilized in adults, its clinical impact in pediatric kidney recipients is not well defined.
methodsWe performed a single-center retrospective study of pediatric kidney transplant recipients who underwent allograft biopsy between September 2023 and September 2025. Histologic diagnoses using 2022 Banff criteria were compared with MMDx molecular interpretations. Agreement between Banff scores and MMDx classifiers was assessed. Discrepancies were defined as discordance in rejection versus no rejection or rejection subtype classification, and changes in clinical management were described.
resultsForty-two biopsies from 38 recipients were analyzed. MMDx scores correlated with Banff indices (TCMR r = 0.55, ABMR r = 0.73, p < 0.001). Rejection vs. no rejection discordance occurred in 24% of biopsies (κ = 0.53) while subtype discordance occurred in 38% (κ = 0.38). In five of seven borderline TCMR cases, MMDx indicated no rejection, and graft function remained stable without treatment. Clinical management changed in 19% of biopsies following MMDx review, typically resulting in an increase in immunosuppression in settings of molecularly diagnosed rejection with equivocal histology.
conclusionsMMDx correlates with histologic assessment and can provide diagnostic clarification in ambiguous pediatric kidney allograft biopsies. Complementary use of histology and molecular diagnostics may inform clinical decision making; prospective studies are needed to determine effects on long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.